Enveric Biosciences (ENVB) CFO awarded 133,333 RSUs in long-term equity grant

Rhea-AI Filing Summary

Coveney Kevin Michael reported acquisition or exercise transactions in this Form 4 filing.

Enveric Biosciences, Inc. reported that Chief Financial Officer Kevin Michael Coveney received a grant of 133,333 restricted stock units under the company’s 2020 Long-Term Incentive Plan. These RSUs are a form of equity compensation and were granted at no cash cost per unit.

For each vested RSU, Coveney will receive one share of common stock, bringing his total reported direct holdings to 180,746 shares after the grant. One-fourth of the RSUs will vest on the one-year anniversary of the grant date, then one‑thirty‑sixth will vest each month, with any remaining RSUs vesting on the fourth anniversary, all conditioned on continued employment.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Coveney Kevin Michael

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	133,333	$0.00	--

Holdings After Transaction: Common Stock — 180,746 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 133,333 units Price per RSU: $0.0000 per unit Shares after transaction: 180,746 shares +3 more

6 metrics

RSUs granted 133,333 units Restricted stock units granted to CFO on 2026-06-01

Price per RSU $0.0000 per unit Grant price for restricted stock units

Shares after transaction 180,746 shares Total common stock beneficially owned following grant

Initial vesting portion One-fourth of RSUs Vests on one-year anniversary of grant date

Ongoing vesting schedule One-thirty-sixth monthly Vests each month after first vesting date

Final vesting date Fourth anniversary Any remaining RSUs vest on fourth anniversary of issuance

Key Terms

restricted stock units, 2020 Long-Term Incentive Plan, vesting, continued employment

4 terms

restricted stock units financial

"Represents the restricted stock units (the "RSUs") granted to the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Long-Term Incentive Plan financial

"granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended"

vesting financial

"One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continued employment financial

"Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company."

Continued employment means that an individual remains in their current job without interruption. For investors, it signals stability and ongoing work that can affect company performance and future prospects. Like a steady heartbeat for a business, sustained employment helps ensure consistent operations and financial health.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coveney Kevin Michael

(Last) (First) (Middle)

245 FIRST STREET, RIVERVIEW II

18TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enveric Biosciences, Inc. [ ENVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		133,333(1)	A	$0	180,746	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

	/s/ Kevin Michael Coveney	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Enveric Biosciences (ENVB) report for its CFO?

Enveric Biosciences reported that CFO Kevin Michael Coveney received 133,333 restricted stock units as equity compensation. The grant, at no cash cost per unit, increases his direct holdings to 180,746 shares, aligning his compensation partly with the company’s stock performance over time.

How many Enveric Biosciences (ENVB) RSUs were granted to the CFO?

The CFO received a grant of 133,333 restricted stock units from Enveric Biosciences. Each RSU converts into one share of common stock as it vests, providing long-term equity-based compensation that vests over several years, subject to the executive’s continued employment with the company.

What is the vesting schedule for the Enveric Biosciences (ENVB) CFO’s RSUs?

One-fourth of the CFO’s RSUs will vest on the one-year anniversary of the grant date. After that, one‑thirty‑sixth of the RSUs will vest monthly, and any remaining RSUs will vest on the fourth anniversary, all contingent on continued employment at Enveric Biosciences.

Did the Enveric Biosciences (ENVB) CFO pay for the newly granted RSUs?

The Form 4 shows a transaction price per share of $0.0000 for the CFO’s RSU grant. This indicates the restricted stock units were awarded as compensation rather than purchased in the open market, consistent with typical long-term incentive plan structures for executives.

How many Enveric Biosciences (ENVB) shares does the CFO hold after this RSU grant?

After the RSU grant, the Form 4 reports that CFO Kevin Michael Coveney beneficially owns 180,746 shares of common stock directly. This figure includes the impact of the 133,333 restricted stock units granted, which will convert into shares as they vest over time.